Goldman Sachs
MNPR icon

Goldman Sachs’s Monopar Therapeutics MNPR Stock Holding History

Goldman Sachs’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9M Buy
34,710
+24,349
+235% +$1.47M ﹤0.01% 4585
2025
Q4 		$677K Buy
10,361
+3,836
+59% +$313K ﹤0.01% 5412
2025
Q3 		$533K Buy
+6,525
New +$292K ﹤0.01% 5473
2025
Q2 		– Sell
-18,480
Closed -$673K – 6299
2025
Q1 		$673K Buy
+18,480
New +$666K ﹤0.01% 4989

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's MNPR Position: Q1 2026 in Review

Goldman Sachs increased its Monopar Therapeutics (MNPR) stake by 235% in Q1 2026, buying an estimated $1.47M and bringing the position to 34,710 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4585.

Goldman Sachs first reported a position in MNPR in Q1 2025 and has held it in 4 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Goldman Sachs held 34,710 shares of Monopar Therapeutics worth $1.9M as of Q1 2026.
  • Goldman Sachs bought 24,349 Monopar Therapeutics shares in Q1 2026, an estimated $1.47M.
  • Monopar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4585 holding.
  • Goldman Sachs first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.